<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03556631</url>
  </required_header>
  <id_info>
    <org_study_id>SZLY2018009</org_study_id>
    <nct_id>NCT03556631</nct_id>
  </id_info>
  <brief_title>Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Outcomes in Type 1 Diabetes</brief_title>
  <official_title>Effect of Live Combined Bifidobacterium and Lactobacillus on Glycemic Control and Other Diabetes‑Related Outcomes in People With Type 1 Diabetes:a Single-blind Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim Evidence of a possible connection between gut microbiota and several physiological
      processes linked to type 1 diabetes is increasing. However, the effect of multistrain
      probiotics in people with type 1 diabetes remains unclear. This study investigated the effect
      of live combined Bifidobacterium and Lactobacillus preparation on glycemic control and other
      diabetes-related outcomes in people with type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Design A randomized, single-blind, parallel-group, controlled clinical trial. Setting
      Diabetes clinic of a teaching hospital in Shenzhen China Participants A total of 30
      participants with type 1 diabetes, aged 18-60 years, will be recruited and randomly assigned
      to receive either probiotics (n = 15) or placebo (n = 15) for 12 weeks.

      Outcomes Primary outcomes were glycemic control related parameters, and secondary outcomes
      were anthropomorphic variables, lipid profile, blood pressure and high-sensitivity C-reactive
      protein. The gut microbiota profile will be analyzed before and after intervention and
      between groups.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>hemoglobin A1c in percentage</measure>
    <time_frame>3 months</time_frame>
    <description>analyze the change of hemoglobin A1c between two groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>weight in kilograms</measure>
    <time_frame>3 months</time_frame>
    <description>analyze the change of weight in kilograms between two groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Probiotics</condition>
  <arm_group>
    <arm_group_label>probiotics group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>live combined Bifidobacterium and Lactobacillus tablets were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo were given to the participants according to their group assignment ,4 tablets ,tid, for 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>live combined Bifidobacterium and Lactobacillus Tablets</intervention_name>
    <description>take the live combined Bifidobacterium and Lactobacillus Tablets 4# or placebo twice a day</description>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_label>probiotics group</arm_group_label>
    <other_name>probiotics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        type 1 diabetes patients ,age 18-60years old,18 Kg/m2≤BMI≤30Kg/m2, 7.0mmol/L＜fasting blood
        glucose ＜13.0mmol/L；HbA1c≤10%，ketonuria (-)；

        Exclusion Criteria:

        pregnancy, lactation, having other severe chronic illnesses.taking other anti-diabetic
        drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ping Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>associate chief physician</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xiuzhen Zhang</last_name>
    <phone>86-13714902238</phone>
    <email>876538754@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ping Xu</last_name>
    <phone>86-13692156916</phone>
  </overall_contact_backup>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>May 22, 2018</study_first_submitted>
  <study_first_submitted_qc>June 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2018</study_first_posted>
  <last_update_submitted>July 13, 2018</last_update_submitted>
  <last_update_submitted_qc>July 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

